Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(10%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
6
60%
Ph phase_3
1
10%
Ph not_applicable
1
10%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(1)
Other(4)

Detailed Status

Not yet recruiting4
unknown4
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting440%
active_not_recruiting110%
unknown440%
completed110%

Recent Activity

1 active trials
Showing 5 of 10
not_yet_recruitingphase_2

Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM

NCT07381309
not_yet_recruitingphase_2

H101 Plus TACE for r/m HNSCC

NCT07398664
not_yet_recruitingphase_2

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

NCT06196671
not_yet_recruitingphase_2

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

NCT06919848
completedphase_1

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

NCT05303090
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07381309Phase 2

Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM

Not Yet Recruiting
NCT07398664Phase 2

H101 Plus TACE for r/m HNSCC

Not Yet Recruiting
NCT06196671Phase 2

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Not Yet Recruiting
NCT06919848Phase 2

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

Not Yet Recruiting
NCT05303090Phase 1

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Completed
NCT05051696Phase 2

Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Active Not Recruiting
NCT05823987Phase 2

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

Unknown
NCT05303844Phase 1

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Unknown
NCT03780049Phase 3

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Unknown
NCT03790059Not Applicable

Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10